Monetary policy has been a disappointment for the market but for the right reasons, he says.
The government’s plan to push ahead with reforms agenda augurs well for economy, says research director of economic policy think tank.
The government should do more to boost consumer sentiment, says chief economist at ZyFin Research.
The Indian venture debt arm of SVB was acquired and rebranded by Temasek.
Any further uptick in global oil prices could pull up inflation, he says.
Jury is still out on which single-specialty healthcare domain would sustain, he says.
Pai says Indian HNIs should invest in startups as they can generate high returns with some risk.
Ghosh says Ujjivan doubled its loan book size to around Rs 3,200 crore in FY15.
Funding is not a big priority at the moment, they say.
The firm has 100 odd branches.
Co-founder of the PE firm says India is best placed in risk-reward ratio among emerging markets.
The managing partner of the PE firm says gross IRR across funds has been 24-28 per cent.
The former CEO of Fortis says he is convinced about building a pan-Asia healthcare business.
It invests $5-15 million in portfolio companies over a period.
The firm is looking to double its inventory to 50,000 properties in a year.
The firm has just raised the third-largest pool of VC money to invest in India.
The surge in valuation has made 2015 a tough year for investments, says Chandra.
Velu says the market for medical devices is untapped.
He says if GPs generate predictable modest returns, LPs would be happy.